# Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis

> **NCT01034306** · PHASE2 · COMPLETED · sponsor: **Can-Fite BioPharma** · enrollment: 79 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** CF101
- **DRUG:** Placebo control

## Key facts

- **NCT ID:** NCT01034306
- **Lead sponsor:** Can-Fite BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2022-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01034306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01034306, "Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01034306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*